Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | BLM | P54132 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.46 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.46 |
| ▸ | GABRP | O00591 | 1/20 | 0.46 |
| ▸ | GABRD | O14764 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.46 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.46 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.46 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.46 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL39930 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A | |
| SCHEMBL515661 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A | |
| SCHEMBL515689 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A | |
| SCHEMBL912891 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A | |
| SCHEMBL23722964 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A | |
| SCHEMBL561138 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A | |
| SCHEMBL23515345 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A | |
| SCHEMBL1578111 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A | |
| SCHEMBL22777473 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A | |
| SCHEMBL17932953 | 1.00 | LMNA (0.46) | LMNABLMTSHRTHRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 347 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122074077-A | Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte stimulating hormone analogs for imaging or therapy | 省卫生服务机构 | 2026-05-22 | — | — | CN | claimed |
| CN-122059930-A | Cdc25 phosphatase degradation agent based on quinoline dione skeleton, and preparation method and application thereof | 山东大学 | 2026-05-19 | — | — | CN | claimed |
| EP-4736944-A2 | POLYPEPTIDES AND USES THEREOF | MedImmune Limited (GB) | 2026-05-06 | — | — | EP | claimed |
| US-20260077073-A1 | GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF | ALPHA 9 ONCOLOGY INC (CA) | 2026-03-19 | — | — | US | claimed |
| WO-2025147774-A1 | COMPOSITIONS TARGETING BRADYKININ RECEPTOR B1 FOR MEDICAL IMAGING AND TREATMENT OF CANCER AND OTHER DISORDERS | ALPHA-9 ONCOLOGY INC. (CA) | 2025-07-17 | — | — | WO | claimed |
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) | 2025-07-08 | — | — | US | claimed |
| US-20250195702-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-06-19 | — | — | US | claimed |
| WO-2025059775-A1 | RADIOLABELED MELANOCORTIN 1 RECEPTOR-SPECIFIC ALPHA-MELANOCYTE-STIMULATING HORMONE ANALOGUES FOR IMAGING OR THERAPY | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-03-27 | — | — | WO | claimed |
| WO-2025054727-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2025-03-20 | — | — | WO | claimed |
| CN-119654040-A | Method for regulating and controlling crystallization of perovskite material by vacuum vapor deposition | 南京大学 | 2025-03-18 | — | — | CN | claimed |
| US-20240010684-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AG (DE) | 2024-01-11 | — | — | US | claimed |
| WO-2023178449-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2023-09-28 | — | — | WO | claimed |
| EP-4240750-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2023-09-13 | — | — | EP | claimed |
| EP-4011904-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | Bayer Aktiengesellschaft (DE) | 2022-06-15 | — | — | EP | claimed |
| WO-2022096394-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-12 | — | — | WO | claimed |
| US-20210402016-A1 | RADIOLABELED BOMBESIN-DERIVED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2021-12-30 | — | — | US | claimed |
| CN-113454098-A | Radiolabeled bombesin derivative compounds for in vivo imaging of Gastrin Releasing Peptide Receptor (GRPR) and treatment of GRPR related disorders | 省卫生服务机构 | 2021-09-28 | — | — | CN | claimed |
| EP-3880691-A1 | RADIOLABELED BOMBESIN-DERIVED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | Provincial Health Services Authority (CA) | 2021-09-22 | — | — | EP | claimed |
| WO-2021068051-A1 | RADIOLABELED BOMBESIN-DERIVED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2021-04-15 | — | — | WO | claimed |
| US-9624283-B2 | Peptide compounds and methods of production and use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2017-04-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12351573-B2 | Compounds for use in synthesis of peptidomimetics | DNPEP, NPEPPS, PAM | LMNA 4762/4885BLM 3782/4885TSHR 1283/4885 |
| US-20210402016-A1 | RADIOLABELED BOMBESIN-DERIVED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | GRPR, NPY1R, GIPR | LMNA 696/4885BLM 2838/4885TSHR 50/4885 |
| US-20250195702-A1 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | GRPR, NPY5R, NPY2R | LMNA 1057/4885BLM 1090/4885TSHR 77/4885 |
| US-20260077073-A1 | GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF | GRPR, GIPR, GLP1R | LMNA 785/4885BLM 2015/4885TSHR 53/4885 |
| US-20240010684-A1 | MASP INHIBITORY COMPOUNDS AND USES THEREOF | MASP2, SPINT2, SERPINB1 | LMNA 800/4885BLM 2818/4885TSHR 3678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.